AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer—2026 Update

作者：Andreas Hartkopf, Ute-Susann Albert, Rupert Bartsch, Ingo Bauerfeind, Maggie Banys‐Paluchowski, Vesna Bjelic‐Radisic, Jens‐Uwe Blohmer, Peter Dall, Eva Maria Fallenberg, Peter A. Fasching, Michael Friedrich, Oleg Gluz, N Harbeck, Jörg Heil, Juliane Hörner-Rieber, Jens Huober, W Janni, Hans-Heinrich Kreipe, David Krug, Thorsten Kühn, Sherko Kümmel, Sibylle Loibl, Diana Lüftner, Michael Patrick Lux, Nicolai Maass, Marion Tina van Mackelenbergh, Christoph Mundhenke, Tjoung-Won Park-Simon, Mattea Reinisch, Toralf Reimer, Kerstin Rhiem, Achim Rody, Andreas Schneeweiß, Florian Schütz, Hans‐Peter Sinn, Christine Solbach, Erich‐Franz Solomayer, Elmar Stickeler, Marc Thill, Michael Untch, Isabell Witzel, Achim Wöckel, Rachel Wuerstlein, Nina Ditsch, Tanja Fehm, Volkmar Müller, Marcus Schmidt · 发表于：The Breast · 年份：2026 · DOI：10.1016/j.breast.2026.104873 · 研究领域：Breast Cancer Treatment Studies、Advanced Breast Cancer Therapies、Breast Lesions and Carcinomas

Biomarkers are integral to modern breast cancer management by providing essential information for prognosis and treatment selection. This review presents the 2026 update of the recommendations of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) on therapy-relevant prognostic and predictive biomarkers. The recommendations are based on a structured evaluation of the most recent and clinically relevant evidence using the AGO grading system to support decision-making in routine clinical practice.